Skip to Main Content

Paper Details

Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
J Nucl Med
0
2023
C1D15, C1D15 SUL, ER, ER-negative, HER2-positive breast cancer, F-FDG, HER2, HER2-Positive Breast Cancer, HER2-positive breast cancer, Patients, SUL, estrogen, estrogen receptor, human epidermal growth factor receptor 2, patients, pertuzumab, trastuzumab
Author NameAffiliation
Lisa A CareyUniversity of North Carolina
Minetta C LiuMayo Clinic
Mothaffar F RimawiBaylor College of Medicine
Anna Maria StornioloMelvin and Bren Simon Comprehensive Cancer Center, Indiana University
Eric P WinerYale Cancer Center
Ian E KropYale Cancer Center
Antonio C WolffSidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Richard L WahlWashington University
Vered StearnsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins
  • 1 - 9

Datasets

Release 1.2